Pre-order Enquiry
Request Free Sample
Global Paclitaxel Injection Market Growth 2019-2024
SKU ID : LPI-13827517 | Publishing Date : 11-Feb-2019 | No. of pages : 166
Request Sample
Request Customization
Check Discounts
Paclitaxel Injection is a kind of anti-cancer injection taking paclitaxel API as raw material. It is mainly used in breast cancer, ovarian cancer and other cancers.
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.
In recent years, the growing population and increasing disease incidence of ovarian cancer, breast cancer and other cancers drive the global paclitaxel injection industry developing.
In the past five years from 2010-2014, global paclitaxel injection industry developed fast with a larger than 15% annual production growth rate. In China, due to the late start, the production growth rate is 12%~17%, which is a little lower than global average.
In the next few years, with the growing attention on women cancers from the whole society and much larger investment on R&D of paclitaxel injection, this industry will continue developing at a high speed. What’s more, because of the high gross profit of producing and selling paclitaxel injection, more and more investors will enter into this industry.
At present, the production of paclitaxel injection mainly concentrated in US, China and EU, the three regions produced about 77.30% of the global total products. Of those, US are the largest production region with a 42.69% of global production market share.
In the future, with the expanded capacity of paclitaxel injection, the manufacturers will face the high risk of price and gross margin decline.
According to this study, over the next five years the Paclitaxel Injection market will register a 11.0% CAGR in terms of revenue, the global market size will reach US$ 3680 million by 2024, from US$ 2180 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Paclitaxel Injection business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Paclitaxel Injection market by product type, application, key manufacturers and key regions and countries.
This study considers the Paclitaxel Injection value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Drug Strength
Raw meterial Paclitaxel API source
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Ovarian cancer
Breast cancer
Cervical cancer
Pancreatic cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Khandelwal Laboratories
Luye Pharma
Beijing Youcare
Beijing Union
Haiyao
Chuntch
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Paclitaxel Injection consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Paclitaxel Injection market by identifying its various subsegments.
Focuses on the key global Paclitaxel Injection manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Paclitaxel Injection with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Paclitaxel Injection submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.
In recent years, the growing population and increasing disease incidence of ovarian cancer, breast cancer and other cancers drive the global paclitaxel injection industry developing.
In the past five years from 2010-2014, global paclitaxel injection industry developed fast with a larger than 15% annual production growth rate. In China, due to the late start, the production growth rate is 12%~17%, which is a little lower than global average.
In the next few years, with the growing attention on women cancers from the whole society and much larger investment on R&D of paclitaxel injection, this industry will continue developing at a high speed. What’s more, because of the high gross profit of producing and selling paclitaxel injection, more and more investors will enter into this industry.
At present, the production of paclitaxel injection mainly concentrated in US, China and EU, the three regions produced about 77.30% of the global total products. Of those, US are the largest production region with a 42.69% of global production market share.
In the future, with the expanded capacity of paclitaxel injection, the manufacturers will face the high risk of price and gross margin decline.
According to this study, over the next five years the Paclitaxel Injection market will register a 11.0% CAGR in terms of revenue, the global market size will reach US$ 3680 million by 2024, from US$ 2180 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Paclitaxel Injection business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Paclitaxel Injection market by product type, application, key manufacturers and key regions and countries.
This study considers the Paclitaxel Injection value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Drug Strength
Raw meterial Paclitaxel API source
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Ovarian cancer
Breast cancer
Cervical cancer
Pancreatic cancer
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Khandelwal Laboratories
Luye Pharma
Beijing Youcare
Beijing Union
Haiyao
Chuntch
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Paclitaxel Injection consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Paclitaxel Injection market by identifying its various subsegments.
Focuses on the key global Paclitaxel Injection manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Paclitaxel Injection with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Paclitaxel Injection submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
